Pure Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.50 Cr
as on 24-10-2024
- Company Age 44 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 27.13 Cr
as on 24-10-2024
- Revenue -23.70%
(FY 2023)
- Profit -45.64%
(FY 2023)
- Ebitda 15.56%
(FY 2023)
- Net Worth -4.35%
(FY 2023)
- Total Assets -3.22%
(FY 2023)
About Pure Pharma
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 2.50 Cr.
The company has closed loans amounting to ₹27.13 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pankaj Badlani, Mahesh Badlani, and Subhash Rijhwani serve as directors at the Company.
- CIN/LLPIN
U24232MP1980PLC001647
- Company No.
001647
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Aug 1980
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pure Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhash Rijhwani  | Director | 30-Mar-1995 | Current |
| Pankaj Badlani | Director | 16-May-2019 | Current |
| Mahesh Badlani | Director | 01-Apr-2001 | Current |
Financial Performance of Pure Pharma.
Pure Pharma Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.7% decrease. The company also saw a substantial fall in profitability, with a 45.64% decrease in profit. The company's net worth dipped by a decrease of 4.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pure Pharma?
In 2021, Pure Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Promed Laboratories Private LimitedActive 53 years 4 monthsPankaj Badlani, Mahesh Badlani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Madhya Pradesh Financial Corporation Creation Date: 28 Mar 2011 | ₹1.50 Cr | Satisfied |
Madhya Pradesh Financial Corporation Creation Date: 23 Mar 2010 | ₹1.50 Cr | Satisfied |
State Bank Of India Creation Date: 14 Oct 2009 | ₹7.50 M | Satisfied |
How Many Employees Work at Pure Pharma?
Pure Pharma has a workforce of 7 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pure Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pure Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
